Drug firm Granules India today said it has received Establishment Inspection Report (EIR) from the US health regulator for the OmniChem facility at Vizag, Andhra Pradesh.
OmniChem facility is operated by 50:50 joint venture of Granules India and Ajinimoto OmniChem N V, it said in a filing on BSE.
The United States Food and Drug Administration (USFDA) has issued EIR for the company's OmniChem facility, it added.
"This facility was inspected by the USFDA in December 2016 and there were seven observations during the inspection. The facility manufactures Active Pharmaceutical Ingredients (API) intermediates," Granules India said.
Shares of Granules India were today trading at Rs 122 per scrip on BSE, up 6.50 per cent fom its previous close.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)